Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

64 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effects of combined ezetimibe and simvastatin therapy as compared with simvastatin alone in patients with type 2 diabetes: a prospective randomized double-blind clinical trial.
Ruggenenti P, Cattaneo D, Rota S, Iliev I, Parvanova A, Diadei O, Ene-Iordache B, Ferrari S, Bossi AC, Trevisan R, Belviso A, Remuzzi G; Ezetimibe and Simvastatin in Dyslipidemia of Diabetes (ESD) Study Group. Ruggenenti P, et al. Among authors: bossi ac. Diabetes Care. 2010 Sep;33(9):1954-6. doi: 10.2337/dc10-0320. Epub 2010 Jun 21. Diabetes Care. 2010. PMID: 20566677 Free PMC article. Clinical Trial.
Moderate salt restriction with or without paricalcitol in type 2 diabetes and losartan-resistant macroalbuminuria (PROCEED): a randomised, double-blind, placebo-controlled, crossover trial.
Parvanova A, Trillini M, Podestà MA, Iliev IP, Ruggiero B, Abbate M, Perna A, Peraro F, Diadei O, Rubis N, Gaspari F, Carrara F, Stucchi N, Belviso A, Bossi AC, Trevisan R, Remuzzi G, de Borst M, Ruggenenti P; PROCEED Study Organization and the Scientific Writing Academy (SWA) 2016. Parvanova A, et al. Among authors: bossi ac. Lancet Diabetes Endocrinol. 2018 Jan;6(1):27-40. doi: 10.1016/S2213-8587(17)30359-5. Epub 2017 Nov 2. Lancet Diabetes Endocrinol. 2018. PMID: 29104158 Clinical Trial.
Effects of valsartan, benazepril and their combination in overt nephropathy of type 2 diabetes: A prospective, randomized, controlled trial.
Ruggenenti P, Trillini M, P Barlovic D, Cortinovis M, Pisani A, Parvanova A, Iliev IP, Ruggiero B, Rota S, Aparicio MC, Perna A, Peraro F, Diadei O, Gaspari F, Carrara F, Stucchi N, Martinetti D, Janez A, Gregoric N, Riccio E, Bossi AC, Trevisan R, Manunta P, Battaglia G, David S, Aucella F, Belviso A, Satta A, Remuzzi G; VALID Study Organization. Ruggenenti P, et al. Among authors: bossi ac. Diabetes Obes Metab. 2019 May;21(5):1177-1190. doi: 10.1111/dom.13639. Epub 2019 Feb 22. Diabetes Obes Metab. 2019. PMID: 30793466 Clinical Trial.
Preventing microalbuminuria with benazepril, valsartan, and benazepril-valsartan combination therapy in diabetic patients with high-normal albuminuria: A prospective, randomized, open-label, blinded endpoint (PROBE) study.
Ruggenenti P, Cortinovis M, Parvanova A, Trillini M, Iliev IP, Bossi AC, Belviso A, Aparicio MC, Trevisan R, Rota S, Perna A, Peracchi T, Rubis N, Martinetti D, Prandini S, Gaspari F, Carrara F, De Cosmo S, Tonolo G, Mangili R, Remuzzi G; VARIETY Study Organization. Ruggenenti P, et al. Among authors: bossi ac. PLoS Med. 2021 Jul 14;18(7):e1003691. doi: 10.1371/journal.pmed.1003691. eCollection 2021 Jul. PLoS Med. 2021. PMID: 34260595 Free PMC article. Clinical Trial.
Blood Pressure and Metabolic Effects of Acetyl-l-Carnitine in Type 2 Diabetes: DIABASI Randomized Controlled Trial.
Parvanova A, Trillini M, Podestà MA, Iliev IP, Aparicio C, Perna A, Peraro F, Rubis N, Gaspari F, Cannata A, Ferrari S, Bossi AC, Trevisan R, Parameswaran S, Chávez-Iñiguez JS, Masnic F, Seck SM, Jiamjariyaporn T, Cortinovis M, Perico L, Sharma K, Remuzzi G, Ruggenenti P, Warnock DG. Parvanova A, et al. Among authors: bossi ac. J Endocr Soc. 2018 Mar 22;2(5):420-436. doi: 10.1210/js.2017-00426. eCollection 2018 May 1. J Endocr Soc. 2018. PMID: 29696241 Free PMC article.
Long-term kidney and systemic effects of calorie restriction in overweight or obese type 2 diabetic patients (C.Re.S.O. 2 randomized controlled trial).
Ruggenenti P, Cortinovis M, Trillini M, Parvanova A, Abbate M, Satriano C, Salvetti F, Bossi AC, Trevisan R, Perna A, Peracchi T, Rubis N, Diadei O, Martinetti D, Gaspari F, Fontana L, Remuzzi G; CRESO 2 Study; Organization. Ruggenenti P, et al. Among authors: bossi ac. Diabetes Res Clin Pract. 2022 Mar;185:109804. doi: 10.1016/j.diabres.2022.109804. Epub 2022 Feb 24. Diabetes Res Clin Pract. 2022. PMID: 35219762 Free article. Clinical Trial.
Measurable urinary albumin predicts cardiovascular risk among normoalbuminuric patients with type 2 diabetes.
Ruggenenti P, Porrini E, Motterlini N, Perna A, Ilieva AP, Iliev IP, Dodesini AR, Trevisan R, Bossi A, Sampietro G, Capitoni E, Gaspari F, Rubis N, Ene-Iordache B, Remuzzi G; BENEDICT Study Investigators. Ruggenenti P, et al. J Am Soc Nephrol. 2012 Oct;23(10):1717-24. doi: 10.1681/ASN.2012030252. Epub 2012 Aug 30. J Am Soc Nephrol. 2012. PMID: 22935482 Free PMC article. Clinical Trial.
64 results